Bicara Therapeutics Inc. 8-K

What Happened
Bicara Therapeutics announced an underwritten public offering that closed Feb. 26, 2026. The company sold 7,175,000 firm shares of common stock at $16.00 per share and issued pre-funded warrants to purchase up to 2,200,000 shares at a public offering price of $15.9999 each. The underwriters exercised a full 30-day option on Feb. 25, 2026 to buy an additional 1,406,250 common shares. Bicara estimates net proceeds from the offering were approximately $161.8 million. The offering was led by Morgan Stanley, TD Securities (USA) and BofA Securities.

Key Details

• Total sold: 7,175,000 firm common shares; 2,200,000 pre-funded warrants; option exercise added 1,406,250 common shares.
• Offering prices: $16.00 per common share; $15.9999 per pre-funded warrant. Net proceeds ≈ $161.8M.
• Pre-funded warrants: immediately exercisable for one share at $0.0001 (cashless exercise allowed); 9.99% ownership cap per holder unless changed with 61 days’ notice (up to 19.99%).
• Preliminary cash position: company disclosed approximately $414.8M in cash, cash equivalents and investments as of Dec. 31, 2025 (unaudited, subject to adjustment; KPMG did not audit/review this figure).

Why It Matters
The transaction significantly bolsters Bicara’s cash resources and is earmarked to support planned regulatory filing and potential U.S. commercial launch of ficerafusp alfa, accelerate development (including first-line HPV‑negative recurrent/metastatic head and neck cancer and less frequent dosing), fund manufacturing and exploratory indication work, and for general corporate purposes. Retail investors should note the pre-funded warrants create potential future dilution if exercised, and the Dec. 31, 2025 cash figure is preliminary and unaudited.